The Role of Peptide YY (PYY)in Inhibiting Food Intake.

University of Copenhagen

Status

Completed

Conditions

Obesity

Treatments

Drug: peripheral Peptide YY administration

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00259233

B208, 2

Details and patient eligibility

About

12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.

Sex

Male

Ages

20 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2)
Body weight fluctuations < 5 kg over the past 2 months.
Blood pressure normal to mildly hypertensive(<159/99 mm Hg)
Non-elite athletes and not planning to change physical activity during the study.

Exclusion criteria

Any physiological or psychological illnesses that could influence the study results.
Regular use of medicine.
Smoking defined as <1 cigarette per day.
Substance abuse or dependence.
Blood donation within the past 3 months before entering the study.
Drinking >21 alcoholic units/week.
Food allergies.
Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.